South Korea · Delayed Price · Currency is KRW ST Pharm Statistics
Total Valuation
ST Pharm has a market cap or net worth of KRW 2.55 trillion. The enterprise value is 2.42 trillion.
| Market Cap | 2.55T |
| Enterprise Value | 2.42T |
Important Dates
The next estimated earnings date is Monday, July 27, 2026.
| Earnings Date | Jul 27, 2026 |
| Ex-Dividend Date | Mar 30, 2026 |
Share Statistics
ST Pharm has 20.86 million shares outstanding. The number of shares has increased by 9.10% in one year.
| Current Share Class | 20.86M |
| Shares Outstanding | 20.86M |
| Shares Change (YoY) | +9.10% |
| Shares Change (QoQ) | -12.14% |
| Owned by Insiders (%) | 7.35% |
| Owned by Institutions (%) | 14.02% |
| Float | 13.13M |
Valuation Ratios
The trailing PE ratio is 36.83 and the forward PE ratio is 33.58. ST Pharm's PEG ratio is 1.13.
| PE Ratio | 36.83 |
| Forward PE | 33.58 |
| PS Ratio | 7.35 |
| PB Ratio | 4.16 |
| P/TBV Ratio | 4.28 |
| P/FCF Ratio | 39.48 |
| P/OCF Ratio | 25.52 |
| PEG Ratio | 1.13 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 24.88, with an EV/FCF ratio of 37.54.
| EV / Earnings | 35.07 |
| EV / Sales | 6.99 |
| EV / EBITDA | 24.88 |
| EV / EBIT | 36.98 |
| EV / FCF | 37.54 |
Financial Position
The company has a current ratio of 2.08, with a Debt / Equity ratio of 0.12.
| Current Ratio | 2.08 |
| Quick Ratio | 1.10 |
| Debt / Equity | 0.12 |
| Debt / EBITDA | 0.76 |
| Debt / FCF | 1.15 |
| Interest Coverage | 16.21 |
Financial Efficiency
Return on equity (ROE) is 12.49% and return on invested capital (ROIC) is 11.32%.
| Return on Equity (ROE) | 12.49% |
| Return on Assets (ROA) | 5.14% |
| Return on Invested Capital (ROIC) | 11.32% |
| Return on Capital Employed (ROCE) | 10.30% |
| Weighted Average Cost of Capital (WACC) | 5.43% |
| Revenue Per Employee | 528.58M |
| Profits Per Employee | 105.36M |
| Employee Count | 655 |
| Asset Turnover | 0.43 |
| Inventory Turnover | 1.18 |
Taxes
In the past 12 months, ST Pharm has paid 5.78 billion in taxes.
| Income Tax | 5.78B |
| Effective Tax Rate | 7.72% |
Stock Price Statistics
The stock price has increased by +45.76% in the last 52 weeks. The beta is 0.22, so ST Pharm's price volatility has been lower than the market average.
| Beta (5Y) | 0.22 |
| 52-Week Price Change | +45.76% |
| 50-Day Moving Average | 139,364.00 |
| 200-Day Moving Average | 123,925.50 |
| Relative Strength Index (RSI) | 42.14 |
| Average Volume (20 Days) | 143,396 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, ST Pharm had revenue of KRW 346.22 billion and earned 69.01 billion in profits. Earnings per share was 3,312.63.
| Revenue | 346.22B |
| Gross Profit | 144.09B |
| Operating Income | 65.44B |
| Pretax Income | 74.83B |
| Net Income | 69.01B |
| EBITDA | 97.26B |
| EBIT | 65.44B |
| Earnings Per Share (EPS) | 3,312.63 |
Balance Sheet
The company has 199.09 billion in cash and 74.33 billion in debt, with a net cash position of 124.76 billion or 5,980.37 per share.
| Cash & Cash Equivalents | 199.09B |
| Total Debt | 74.33B |
| Net Cash | 124.76B |
| Net Cash Per Share | 5,980.37 |
| Equity (Book Value) | 611.25B |
| Book Value Per Share | 29,436.44 |
| Working Capital | 230.78B |
Cash Flow
In the last 12 months, operating cash flow was 99.72 billion and capital expenditures -35.26 billion, giving a free cash flow of 64.47 billion.
| Operating Cash Flow | 99.72B |
| Capital Expenditures | -35.26B |
| Depreciation & Amortization | 31.82B |
| Net Borrowing | -7.05B |
| Free Cash Flow | 64.47B |
| FCF Per Share | 3,090.18 |
Margins
Gross margin is 41.62%, with operating and profit margins of 18.90% and 19.93%.
| Gross Margin | 41.62% |
| Operating Margin | 18.90% |
| Pretax Margin | 21.61% |
| Profit Margin | 19.93% |
| EBITDA Margin | 28.09% |
| EBIT Margin | 18.90% |
| FCF Margin | 18.62% |
Dividends & Yields
This stock pays an annual dividend of 500.00, which amounts to a dividend yield of 0.41%.
| Dividend Per Share | 500.00 |
| Dividend Yield | 0.41% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 14.60% |
| Buyback Yield | -9.10% |
| Shareholder Yield | -8.69% |
| Earnings Yield | 2.71% |
| FCF Yield | 2.53% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for ST Pharm is 189,090.91, which is 54.99% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 189,090.91 |
| Price Target Difference | 54.99% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (3Y) | 22.02% |
| EPS Growth Forecast (3Y) | 28.82% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
ST Pharm has an Altman Z-Score of 6.71 and a Piotroski F-Score of 6.
| Altman Z-Score | 6.71 |
| Piotroski F-Score | 6 |